Journal article
Endogenous IL-21 restricts CD8 T cell expansion and is not required for tumor immunity
H Søndergaard, JM Coquet, AP Uldrich, N McLaughlin, DI Godfrey, PV Sivakumar, K Skak, MJ Smyth
Journal of Immunology | AMER ASSOC IMMUNOLOGISTS | Published : 2009
Abstract
IL-21 has antitumor activity through actions on NK cells and CD8 + T cells, and is currently in clinical development for the treatment of cancer. However, no studies have addressed the role of endogenous IL-21 in tumor immunity. In this study, we have studied both primary and secondary immune responses in IL-21-/- and IL-21R-/- mice against several experimental tumors. We found intact immune surveillance toward methylcholanthrene-induced sarcomas in IL-21-/- and IL-21R -/- mice compared with wild-type mice and B16 melanomas showed equal growth kinetics and development of lung metastases. IL-21R-/- mice showed competent NK cell-mediated rejection of NKG2D ligand (Rae1β) expressing H-2b- RMAS ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by Grant 454569 from the National Health and Medical Research Council of Australia Program (to M.J.S., and D.I.G.), by a Cancer Research Institute Postgraduate Scholarship (to J.M.C.), a Doherty Fellowship (to A.P.U.), and by National Health and Medical Research Council Research Fellowships (to M.M. and D.I.G.). D.I.G. and M.J.S. have received research support from Novo Nordisk A/S,